Can anti-IgE be used to treat allergy?

@article{Davis2004CanAB,
  title={Can anti-IgE be used to treat allergy?},
  author={Frances M. Davis and Lani A. Gossett and Kristi Pinkston and Ruey S. Liou and L K Sun and Y. W. Kim and Nancy T. Chang and T. W. Chang and Kathrin Wagner and J P Bews and Volker Brinkmann and Harry Towbin and N. Subramanian and Christoph H. Heusser},
  journal={Springer Seminars in Immunopathology},
  year={2004},
  volume={15},
  pages={51-73}
}
Summary and conclusionA summary of the properties of CGP 51901 is shown in Table 3. On the basis of its binding to IgE and IgE-secreting cells and its activity in vitro and in vivo, CGP 51901 is expected to be able to decrease serum IgE by direct clearance of IgE and by reduction of the numbers and productivity of IgE-secreting cells. The end result of reduction of IgE in the circulation and on mast cells is expected to be the attenuation of IgE-mediated reactions and the improvement in allergy… 

Anti-IgE as a mast cell-stabilizing therapeutic agent.

  • T. ChangY. Shiung
  • Biology, Medicine
    The Journal of allergy and clinical immunology
  • 2006

Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.

A pharmacokinetic-pharmacodynamic model incorporating omalizumab-IgE binding and feedback for control of IgE production indicates that omalIZumab reduces production of IgN, raising the possibility that indefinite treatment may not be required, only for perhaps a few years.

Will Anti-IgE Therapy Compromise Normal

The IgE-mediated immune mechanism seems to have a modest role in the protection of human subjects against the infection of parasitic worms since the defense function is handled by several redundant immune mechanisms.

Effect of anti-IgE therapy in patients with peanut allergy.

A 450-mg dose of TNX-901 significantly and substantially increased the threshold of sensitivity to peanut on oral food challenge from a level equal to approximately half a peanut to one equal to almost nine peanuts, an effect that should translate into protection against most unintended ingestions of peanuts.

Development and characterization of a novel anti-IgE monoclonal antibody.

B cells and food allergy

B cells play several roles in the development of food allergy versus tolerance and can be employed in other atopic diseases to better understand their pathogenesis and create new avenues for treatment.

Inhibition of human airway sensitization by a novel monoclonal anti-IgE antibody, 17-9.

It is concluded that allergen responses in sensitized human airways are dependent on IgE levels in the sensitizing serum while nonspecific (hyper)responsiveness depends on serum factors other than IgE.

Anti-IgE Therapy

Omalizumab, a recombinant humanized IgG1 antibody with a unique set of binding specificities toward human IgE, has been approved in the United States and Australia for treating adult and adolescent patients with moderate to severe asthma and for protecting against anaphylactic reactions to peanuts.

Molecular aspects of allergy.

References

SHOWING 1-10 OF 49 REFERENCES

Parasites and allergy: evidence for a ‘cause and effect’ relationship

  • R. MoqbelD. Pritchard
  • Biology, Medicine
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 1990
The IgE/mast cell system almost certainly evolved to enhance protection rather than simply to mediate clinical allergic reactions against normally harmless substances to which man is constantly exposed.

IL-4 requirements for the generation of secondary in vivo IgE responses.

Evidence is provided that IL-4 is required for virgin B lymphocytes to develop into IgE-expressing cells, but is not required for B cells that express intrinsic membrane IgE to differentiate into Ig E-secreting cells in a T-dependent response.

Anti-human IgG causes basophil histamine release by acting on IgG-IgE complexes bound to IgE receptors.

The ability of anti-human IgG antibodies to induce histamine release from human basophils is reexamined and it is concluded that anti-IgG-induced release occurs as a result of binding to IgG anti-iGE antibodies and cross-linking of the IgE receptors on basophil.

Human IgE-binding factors.

IgE-binding factors and regulation of the IgE antibody response.

  • K. Ishizaka
  • Biology, Medicine
    Annual review of immunology
  • 1988
If the same procedures would be effective for human T cells of allergic patients, it would be possible to generate antigen-specific suppressor T cells from their T cell population in vitro and to establish T cell hybridomas that produce allergen-specific GIF(TsF).

New concepts of IgE regulation.

It is demonstrated that in certain established immune situations the IgE response may become independent of IL-4, namely in the spontaneous in vitro IgE expression of cells from atopic individuals as well as in an in vitro antigen-induced secondary IgEresponse of spleen cells derived from previously immunized mice.

Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1.

Results indicate an important physiologic role for BSF-1 in the generation of IgE antibody responses and suggest means for limiting the production of antibodies responsible for allergic reactions without inhibiting protective antibody responses.

Induction of an auto‐anti‐IgE response in rats. I. Effects on serum IgE concentrations

With a view to specifically suppressing the IgE isotype, rats of high (BN) and low (PVG. RT1u) IgE‐responding phenotypes were immunized with a highly purified rat IgE myeloma (IR2) in an attempt to

Lymphokine control of in vivo immunoglobulin isotype selection.

There is no direct evidence that IL-5 contributes to the generation of in vivo antibody responses, but two general conclusions may also be drawn.

A T cell activity that enhances polyclonal IgE production and its inhibition by interferon-gamma.

The addition of concanavalin A-stimulated supernatants of the helper T cell clone, D9.1, to cultures of lipopolysaccharide (LPS)-stimulated T-depleted mouse spleen cells caused more than a 100-fold